Clinical Trial Update: A Randomized Trial Assessing the Roles of AraC in Newly Diagnosed APL Promyelocytic Leukemia (APL) [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial evaluating the role of cytarabine (Ara-C) in newly diagnosed acute promyelocytic leukemia (APL) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Promyelocytic Leukemia

Drugs mentioned

• Cytarabine (Ara-C) (cytarabine)

Snippet

Sponsor: Groupe d'etude et de travail sur les leucemies aigues promyelocytaires | Conditions: Leukemia, Promyelocytic, Acute | Phase 3 | Status: COMPLETED